Multicenter ||| S:0 E:11 ||| NNP
,  ||| S:11 E:13 ||| ,
randomized ||| S:13 E:23 ||| NN
,  ||| S:23 E:25 ||| ,
parallel-group  ||| S:25 E:40 ||| JJ
study  ||| S:40 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
the  ||| S:49 E:53 ||| DT
safety  ||| S:53 E:60 ||| NN
and  ||| S:60 E:64 ||| CC
effectiveness  ||| S:64 E:78 ||| NN
of  ||| S:78 E:81 ||| IN
onabotulinumtoxinA  ||| S:81 E:100 ||| JJ
and  ||| S:100 E:104 ||| CC
hyaluronic  ||| S:104 E:115 ||| FW
acid  ||| S:115 E:120 ||| FW
dermal  ||| S:120 E:127 ||| FW
fillers  ||| S:127 E:135 ||| FW
( ||| S:135 E:136 ||| -LRB-
24-mg ||| S:136 E:141 ||| FW
/ ||| S:141 E:142 ||| FW
ml  ||| S:142 E:145 ||| FW
smooth ||| S:145 E:151 ||| FW
,  ||| S:151 E:153 ||| ,
cohesive  ||| S:153 E:162 ||| JJ
gel ||| S:162 E:165 ||| NN
)  ||| S:165 E:167 ||| -RRB-
alone  ||| S:167 E:173 ||| RB
and  ||| S:173 E:177 ||| CC
in  ||| S:177 E:180 ||| IN
combination  ||| S:180 E:192 ||| NN
for  ||| S:192 E:196 ||| IN
lower  ||| S:196 E:202 ||| JJR
facial  ||| S:202 E:209 ||| JJ
rejuvenation  ||| S:209 E:222 ||| NN
Combination  ||| S:222 E:234 ||| NNP
treatment  ||| S:234 E:244 ||| NN
with  ||| S:244 E:249 ||| IN
toxins  ||| S:249 E:256 ||| NN
and  ||| S:256 E:260 ||| CC
fillers  ||| S:260 E:268 ||| NN
is  ||| S:268 E:271 ||| VBZ
the  ||| S:271 E:275 ||| DT
standard  ||| S:275 E:284 ||| JJ
regimen  ||| S:284 E:292 ||| NN
in  ||| S:292 E:295 ||| IN
facial  ||| S:295 E:302 ||| JJ
rejuvenation ||| S:302 E:314 ||| NN
.  ||| S:314 E:316 ||| .
Systematic  ||| S:316 E:327 ||| JJ
studies  ||| S:327 E:335 ||| NNS
of  ||| S:335 E:338 ||| IN
botulinum  ||| S:338 E:348 ||| JJ
toxin  ||| S:348 E:354 ||| NN
alone  ||| S:354 E:360 ||| RB
and  ||| S:360 E:364 ||| CC
in  ||| S:364 E:367 ||| IN
combination  ||| S:367 E:379 ||| NN
with  ||| S:379 E:384 ||| IN
hyaluronic  ||| S:384 E:395 ||| JJ
acid  ||| S:395 E:400 ||| NN
( ||| S:400 E:401 ||| -LRB-
HA ||| S:401 E:403 ||| NNP
)  ||| S:403 E:405 ||| -RRB-
have  ||| S:405 E:410 ||| VBP
not ||| S:410 E:413 ||| RB
,  ||| S:413 E:415 ||| ,
however ||| S:415 E:422 ||| RB
,  ||| S:422 E:424 ||| ,
been  ||| S:424 E:429 ||| VBN
conducted  ||| S:429 E:439 ||| VBN
in  ||| S:439 E:442 ||| IN
the  ||| S:442 E:446 ||| DT
lower  ||| S:446 E:452 ||| JJR
face ||| S:452 E:456 ||| NN
.  ||| S:456 E:458 ||| .
To  ||| S:458 E:461 ||| TO
evaluate  ||| S:461 E:470 ||| VB
safety  ||| S:470 E:477 ||| NN
and  ||| S:477 E:481 ||| CC
effectiveness  ||| S:481 E:495 ||| NN
and  ||| S:495 E:499 ||| CC
compare  ||| S:499 E:507 ||| VB
combination  ||| S:507 E:519 ||| NN
treatment  ||| S:519 E:529 ||| NN
with  ||| S:529 E:534 ||| IN
onabotulinumtoxinA  ||| S:534 E:553 ||| JJ
and  ||| S:553 E:557 ||| CC
a  ||| S:557 E:559 ||| DT
24-mg ||| S:559 E:564 ||| CD
/ ||| S:564 E:565 ||| CD
mL  ||| S:565 E:568 ||| JJ
smooth ||| S:568 E:574 ||| JJ
,  ||| S:574 E:576 ||| ,
cohesive  ||| S:576 E:585 ||| FW
HA  ||| S:585 E:588 ||| FW
gel  ||| S:588 E:592 ||| FW
filler  ||| S:592 E:599 ||| FW
with  ||| S:599 E:604 ||| IN
either  ||| S:604 E:611 ||| DT
treatment  ||| S:611 E:621 ||| NN
alone  ||| S:621 E:627 ||| RB
for  ||| S:627 E:631 ||| IN
rejuvenation  ||| S:631 E:644 ||| NN
of  ||| S:644 E:647 ||| IN
the  ||| S:647 E:651 ||| DT
perioral  ||| S:651 E:660 ||| JJ
area  ||| S:660 E:665 ||| NN
and  ||| S:665 E:669 ||| CC
lower  ||| S:669 E:675 ||| JJR
face  ||| S:675 E:680 ||| NN
in  ||| S:680 E:683 ||| IN
female  ||| S:683 E:690 ||| JJ
subjects ||| S:690 E:698 ||| NNS
.  ||| S:698 E:700 ||| .
Ninety  ||| S:700 E:707 ||| JJ
female  ||| S:707 E:714 ||| JJ
participants  ||| S:714 E:727 ||| NNS
aged  ||| S:727 E:732 ||| VBN
35  ||| S:732 E:735 ||| CD
to  ||| S:735 E:738 ||| TO
55  ||| S:738 E:741 ||| CD
were  ||| S:741 E:746 ||| VBD
randomized  ||| S:746 E:757 ||| VBN
to  ||| S:757 E:760 ||| TO
one  ||| S:760 E:764 ||| CD
of  ||| S:764 E:767 ||| IN
three  ||| S:767 E:773 ||| CD
groups ||| S:773 E:779 ||| NNS
:  ||| S:779 E:781 ||| :
24-mg ||| S:781 E:786 ||| FW
/ ||| S:786 E:787 ||| FW
mL  ||| S:787 E:790 ||| FW
cohesive  ||| S:790 E:799 ||| FW
gel  ||| S:799 E:803 ||| FW
alone  ||| S:803 E:809 ||| FW
( ||| S:809 E:810 ||| -LRB-
n=30 ||| S:810 E:814 ||| NNP
) ||| S:814 E:815 ||| -RRB-
,  ||| S:815 E:817 ||| ,
onabotulinumtoxinA  ||| S:817 E:836 ||| JJ
alone  ||| S:836 E:842 ||| NNS
( ||| S:842 E:843 ||| -LRB-
n=30 ||| S:843 E:847 ||| NNP
) ||| S:847 E:848 ||| -RRB-
,  ||| S:848 E:850 ||| ,
or  ||| S:850 E:853 ||| CC
the  ||| S:853 E:857 ||| DT
combination  ||| S:857 E:869 ||| NN
( ||| S:869 E:870 ||| -LRB-
n=30 ||| S:870 E:874 ||| NNP
) ||| S:874 E:875 ||| -RRB-
.  ||| S:875 E:877 ||| .
Effectiveness  ||| S:877 E:891 ||| NN
outcomes  ||| S:891 E:900 ||| NNS
included  ||| S:900 E:909 ||| VBD
perioral ||| S:909 E:917 ||| CD
,  ||| S:917 E:919 ||| ,
lip  ||| S:919 E:923 ||| JJ
fullness ||| S:923 E:931 ||| NN
,  ||| S:931 E:933 ||| ,
and  ||| S:933 E:937 ||| CC
oral  ||| S:937 E:942 ||| JJ
commissure  ||| S:942 E:953 ||| JJ
assessments  ||| S:953 E:965 ||| NNS
and  ||| S:965 E:969 ||| CC
scores  ||| S:969 E:976 ||| NNS
on  ||| S:976 E:979 ||| IN
the  ||| S:979 E:983 ||| DT
Cosmetic  ||| S:983 E:992 ||| NNP
Improvement  ||| S:992 E:1004 ||| NNP
and  ||| S:1004 E:1008 ||| CC
Global  ||| S:1008 E:1015 ||| NNP
Aesthetic  ||| S:1015 E:1025 ||| NNP
Improvement  ||| S:1025 E:1037 ||| NNP
Scales ||| S:1037 E:1043 ||| NNP
.  ||| S:1043 E:1045 ||| .
Adverse  ||| S:1045 E:1053 ||| JJ
events  ||| S:1053 E:1060 ||| NNS
were  ||| S:1060 E:1065 ||| VBD
monitored  ||| S:1065 E:1075 ||| VBN
throughout ||| S:1075 E:1085 ||| IN
.  ||| S:1085 E:1087 ||| .
For  ||| S:1087 E:1091 ||| IN
all  ||| S:1091 E:1095 ||| DT
end  ||| S:1095 E:1099 ||| NN
points  ||| S:1099 E:1106 ||| NNS
and  ||| S:1106 E:1110 ||| CC
most  ||| S:1110 E:1115 ||| JJS
time  ||| S:1115 E:1120 ||| NN
points ||| S:1120 E:1126 ||| NNS
,  ||| S:1126 E:1128 ||| ,
subjects  ||| S:1128 E:1137 ||| VBZ
treated  ||| S:1137 E:1145 ||| VBN
with  ||| S:1145 E:1150 ||| IN
onabotulinumtoxinA  ||| S:1150 E:1169 ||| JJ
plus  ||| S:1169 E:1174 ||| CC
the  ||| S:1174 E:1178 ||| DT
24-mg ||| S:1178 E:1183 ||| CD
/ ||| S:1183 E:1184 ||| CD
mL  ||| S:1184 E:1187 ||| JJ
cohesive  ||| S:1187 E:1196 ||| JJ
gel  ||| S:1196 E:1200 ||| NN
had  ||| S:1200 E:1204 ||| VBD
greater  ||| S:1204 E:1212 ||| JJR
improvement  ||| S:1212 E:1224 ||| NN
from  ||| S:1224 E:1229 ||| IN
baseline  ||| S:1229 E:1238 ||| NN
than  ||| S:1238 E:1243 ||| IN
subjects  ||| S:1243 E:1252 ||| NNS
treated  ||| S:1252 E:1260 ||| VBN
with  ||| S:1260 E:1265 ||| IN
onabotulinumtoxinA  ||| S:1265 E:1284 ||| JJ
or  ||| S:1284 E:1287 ||| CC
the  ||| S:1287 E:1291 ||| DT
24-mg ||| S:1291 E:1296 ||| FW
/ ||| S:1296 E:1297 ||| FW
mL  ||| S:1297 E:1300 ||| FW
cohesive  ||| S:1300 E:1309 ||| FW
gel  ||| S:1309 E:1313 ||| FW
filler  ||| S:1313 E:1320 ||| FW
alone ||| S:1320 E:1325 ||| FW
.  ||| S:1325 E:1327 ||| .
Based  ||| S:1327 E:1333 ||| VBN
on  ||| S:1333 E:1336 ||| IN
a  ||| S:1336 E:1338 ||| DT
range  ||| S:1338 E:1344 ||| NN
of  ||| S:1344 E:1347 ||| IN
end  ||| S:1347 E:1351 ||| NN
points ||| S:1351 E:1357 ||| NNS
,  ||| S:1357 E:1359 ||| ,
onabotulinumtoxinA  ||| S:1359 E:1378 ||| JJ
and  ||| S:1378 E:1382 ||| CC
24-mg ||| S:1382 E:1387 ||| FW
/ ||| S:1387 E:1388 ||| FW
mL  ||| S:1388 E:1391 ||| FW
cohesive  ||| S:1391 E:1400 ||| FW
HA  ||| S:1400 E:1403 ||| FW
gel  ||| S:1403 E:1407 ||| FW
treatments  ||| S:1407 E:1418 ||| NNS
are  ||| S:1418 E:1422 ||| VBP
effective  ||| S:1422 E:1432 ||| JJ
and  ||| S:1432 E:1436 ||| CC
safe  ||| S:1436 E:1441 ||| JJ
when  ||| S:1441 E:1446 ||| WRB
either  ||| S:1446 E:1453 ||| RB
alone  ||| S:1453 E:1459 ||| RB
or  ||| S:1459 E:1462 ||| CC
in  ||| S:1462 E:1465 ||| IN
combination  ||| S:1465 E:1477 ||| NN
to  ||| S:1477 E:1480 ||| TO
rejuvenate  ||| S:1480 E:1491 ||| VB
the  ||| S:1491 E:1495 ||| DT
lower  ||| S:1495 E:1501 ||| JJR
face ||| S:1501 E:1505 ||| NN
.  ||| S:1505 E:1507 ||| .
Combination  ||| S:1507 E:1519 ||| NN
therapy  ||| S:1519 E:1527 ||| NN
is  ||| S:1527 E:1530 ||| VBZ
superior  ||| S:1530 E:1539 ||| JJ
to  ||| S:1539 E:1542 ||| TO
either  ||| S:1542 E:1549 ||| DT
modality  ||| S:1549 E:1558 ||| NN
used  ||| S:1558 E:1563 ||| VBD
alone ||| S:1563 E:1568 ||| RB
.  ||| S:1568 E:1570 ||| .
